Traynor Capital Management Inc. acquired a new position in shares of UiPath Inc. (NYSE:PATH – Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,758 shares of the healthcare company’s stock, valued at approximately $516,000.
Several other hedge funds have also recently bought and sold shares of PATH. Renaissance Capital LLC grew its holdings in shares of UiPath by 3.0% during the first quarter. Renaissance Capital LLC now owns 250,295 shares of the healthcare company’s stock worth $5,674,000 after purchasing an additional 7,269 shares during the last quarter. GAMMA Investing LLC boosted its holdings in UiPath by 40.2% in the first quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock valued at $50,000 after acquiring an additional 632 shares during the last quarter. Quadrature Capital Ltd boosted its holdings in UiPath by 94.4% in the fourth quarter. Quadrature Capital Ltd now owns 253,112 shares of the healthcare company’s stock valued at $6,289,000 after acquiring an additional 122,931 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in UiPath by 50.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 19,135 shares of the healthcare company’s stock valued at $475,000 after acquiring an additional 6,385 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in UiPath by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 38,084,858 shares of the healthcare company’s stock valued at $946,028,000 after purchasing an additional 334,085 shares during the period. 62.50% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $19.79, for a total value of $791,600.00. Following the completion of the transaction, the chief financial officer now owns 946,848 shares of the company’s stock, valued at approximately $18,738,121.92. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 22.37% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Report on UiPath
UiPath Stock Up 0.5 %
Shares of PATH opened at $12.02 on Tuesday. UiPath Inc. has a 12-month low of $11.07 and a 12-month high of $27.87. The business has a 50-day simple moving average of $16.71 and a two-hundred day simple moving average of $21.10.
UiPath (NYSE:PATH – Get Free Report) last issued its earnings results on Wednesday, May 29th. The healthcare company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). UiPath had a negative return on equity of 2.97% and a negative net margin of 6.41%. The business had revenue of $335.11 million during the quarter, compared to analysts’ expectations of $332.84 million. As a group, analysts expect that UiPath Inc. will post -0.2 EPS for the current fiscal year.
UiPath Company Profile
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Further Reading
- Five stocks we like better than UiPath
- Using the MarketBeat Stock Split Calculator
- Tesla Stock: The Pay Package Battle and Its Impact on Investors
- What is Insider Trading? What You Can Learn from Insider Trading
- Call Option Interest Soars in These 3 Stocks
- What Are Dividends? Buy the Best Dividend Stocks
- Top 3 Dividend Stocks Trading Close to 52-Week Low Prices
Want to see what other hedge funds are holding PATH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UiPath Inc. (NYSE:PATH – Free Report).
Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.